アークトゥルス・セラピューティクス・ホールディングスに関するコメント

$アークトゥルス・セラピューティクス・ホールディングス(ARCT.US)$- do your DD- on all positive news from here!
“The most important thing here is that WHO chose ARCT for one of the 4 vaccine candidates and sponsor and fund phase 3 for arct021.
ARCT has very good mRNA platforms, and hence very valuable IPs. Arct021 was the original vaccine candidate to tackle covid19. With the emergence of variants, ARCT has quickly updated and came up with arct154 and arct165. If ARCT can get EUA in Vietnam for arct154, the potential would be immense. Arct021 is a one dose vaccine and that has a lot of advantages. Despite the fact that many may already have been vaccinated, but arct021 can still be effective as a one dose vaccine since from research reports, neutralising antibodies dropped to very low levels after 6 months with the other vaccines. So, arct021, arct154 and arct165 still have very good potentials in the vaccine market and can also be as booster shots.
In the future, if we have another outbreak of diseases, ARCT can be the go-to company to quickly develop a vaccine besides BionTech and Moderna. The mRNA platforms of ARCT, in my opinion, is better than its competitors. Some big pharmas are behind the curve in mRNA technology and they may look to acquire ARCT. The only weakness for ARCT was that it was a standalone biotech and there was no support or tie-up with another big pharma during the covid crisis as compared to BionTech with Pfizer, and Moderna getting lots of funding etc....” qoutes from (Seeking Alpha- comments)

$アークトゥルス・セラピューティクス・ホールディングス(ARCT.US)$ September 7: Replicate Bioscience raises $40 million to develop next-generation MRNA therapies
1. Replicate Bioscience is a biomedical company that designs unique self-replicating RNA(srRNA) in synthetic biology to develop next-generation mRNA therapies.
2. Replicate core technology self-amplifying RNA (saRNA) allows you to amplify more RNA in the body than the first generation oF mRNA vaccines. Because of the time end in the body, it requires multiple and massive doses and increases the toxic side effects. The technical goal is to address these deficiencies.